- Home
- FDMT vs INBX Comparison
FDMT vs INBX Comparison
Compare FDMT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- INBX
- Stock Information
- Founded
- FDMT 2013
- INBX 2010
- Country
- FDMT United States
- INBX United States
- Employees
- FDMT N/A
- INBX N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- INBX Health Care
- Exchange
- FDMT Nasdaq
- INBX Nasdaq
- Market Cap
- FDMT 391.8M
- INBX 430.2M
- IPO Year
- FDMT 2020
- INBX 2020
- Fundamental
- Price
- FDMT $10.81
- INBX $80.98
- Analyst Decision
- FDMT Strong Buy
- INBX Hold
- Analyst Count
- FDMT 9
- INBX 2
- Target Price
- FDMT $30.11
- INBX N/A
- AVG Volume (30 Days)
- FDMT 933.6K
- INBX 734.6K
- Earning Date
- FDMT 11-07-2025
- INBX 11-14-2025
- Dividend Yield
- FDMT N/A
- INBX N/A
- EPS Growth
- FDMT N/A
- INBX N/A
- EPS
- FDMT N/A
- INBX N/A
- Revenue
- FDMT $33,000.00
- INBX $1,400,000.00
- Revenue This Year
- FDMT $8,572.97
- INBX $563.00
- Revenue Next Year
- FDMT $6.05
- INBX $230.77
- P/E Ratio
- FDMT N/A
- INBX N/A
- Revenue Growth
- FDMT N/A
- INBX N/A
- 52 Week Low
- FDMT $2.24
- INBX $10.81
- 52 Week High
- FDMT $12.34
- INBX $86.64
- Technical
- Relative Strength Index (RSI)
- FDMT 56.19
- INBX 82.88
- Support Level
- FDMT $10.33
- INBX $28.16
- Resistance Level
- FDMT $12.00
- INBX $86.62
- Average True Range (ATR)
- FDMT 0.98
- INBX 7.65
- MACD
- FDMT -0.17
- INBX 2.94
- Stochastic Oscillator
- FDMT 38.80
- INBX 90.44
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.